Evidence map›Paper›PMID 42232544›Full record

ArticleFrontiers in oncology2026

CT imaging features of pulmonary SMARCA4-deficient undifferentiated carcinoma: a retrospective case series.

Yujian Liu, Tianjiao Lv, Limei Han, Yuan Li

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yujian LiuDepartment of Radiology, Zigong First People's Hospital, Zigong, Sichuan, China.
Tianjiao LvDepartment of Radiology, Zigong First People's Hospital, Zigong, Sichuan, China.
Limei HanDepartment of Radiology, Zigong First People's Hospital, Zigong, Sichuan, China.
Yuan LiDepartment of Ultrasound, Zigong Fourth People's Hospital, Zigong, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pulmonary SMARCA4-deficient undifferentiated carcinoma is a rare and highly aggressive thoracic malignancy characterized by rapid progression, poor prognosis, and nonspecific imaging features. Although its pathological and molecular characteristics are increasingly recognized, its CT imaging features remain insufficiently characterized. This study aimed to systematically describe the CT imaging features of this entity and to summarize coexisting imaging findings that may assist radiologic suspicion. Methods: This retrospective study included 15 patients with pathologically and immunohistochemically confirmed pulmonary SMARCA4-deficient undifferentiated carcinoma. All patients underwent baseline chest CT before any antitumor treatment, including non-contrast and contrast-enhanced scans. Two experienced thoracic radiologists, blinded to pathological results, independently evaluated tumor location, size, morphology, margins, intratumoral necrosis or cavitation, enhancement characteristics, invasion of adjacent structures, lymphadenopathy, pleural involvement, and distant metastases. Interobserver agreement was assessed using Cohen's κ, and analyses were descriptive. Results: Patients were predominantly middle-aged to elderly men, most with a smoking history, and the majority presented with locally advanced or advanced-stage disease. On CT, tumors typically appeared as solid masses with a median maximum diameter of 3.7 cm (range, 0.6-9.5 cm), nearly half of which were centrally located. Aggressive imaging features were common, including spiculated margins (93.3%), intratumoral necrosis (86.7%), and cavitation (46.7%). Contrast-enhanced CT frequently demonstrated heterogeneous moderate-to-marked enhancement. Invasion of adjacent structures was prevalent, including bronchial involvement (86.7%), vascular invasion (80.0%), and mediastinal invasion (66.7%). Lymph node metastases were observed in 86.7% of cases, often as conglomerated lymphadenopathy (73.3%). Key imaging features showed good-to-excellent interobserver agreement. All cases demonstrated loss of SMARCA4 (BRG1) nuclear expression with retained INI-1. Conclusion: Pulmonary SMARCA4-deficient undifferentiated carcinoma showed a reproducible aggressive CT imaging profile in this cohort, characterized by marked heterogeneity, necrosis or cavitation, multi-structure invasion, and conglomerated lymphadenopathy. Although these findings are not individually specific, their co-occurrence may help raise suspicion for this entity over other aggressive thoracic malignancies with overlapping imaging features and support earlier targeted immunohistochemical confirmation. Further multicenter studies are needed to validate this CT imaging profile and clarify its clinical relevance.

Indexed as

aggressive imaging featurescomputed tomographylungSMARCA4 deficiencyundifferentiated carcinoma

Identifiers

PMID42232544
PMCPMC13222827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.